KR20100128326A - 암 치료 및 진단을 위한 표적 유전자인 ｃ2ｏｒｆ18 - Google Patents

암 치료 및 진단을 위한 표적 유전자인 ｃ2ｏｒｆ18 Download PDF

Info

Publication number
KR20100128326A
KR20100128326A KR1020107022812A KR20107022812A KR20100128326A KR 20100128326 A KR20100128326 A KR 20100128326A KR 1020107022812 A KR1020107022812 A KR 1020107022812A KR 20107022812 A KR20107022812 A KR 20107022812A KR 20100128326 A KR20100128326 A KR 20100128326A
Authority
KR
South Korea
Prior art keywords
c2orf18
cancer
polypeptide
gene
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107022812A
Other languages
English (en)
Korean (ko)
Inventor
유스케 나카무라
히데와키 나카가와
슈이치 나카츠루
Original Assignee
온코세라피 사이언스 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코세라피 사이언스 가부시키가이샤 filed Critical 온코세라피 사이언스 가부시키가이샤
Publication of KR20100128326A publication Critical patent/KR20100128326A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107022812A 2008-03-12 2009-03-10 암 치료 및 진단을 위한 표적 유전자인 ｃ2ｏｒｆ18 Withdrawn KR20100128326A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3603508P 2008-03-12 2008-03-12
US61/036,035 2008-03-12

Publications (1)

Publication Number Publication Date
KR20100128326A true KR20100128326A (ko) 2010-12-07

Family

ID=41064968

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107022812A Withdrawn KR20100128326A (ko) 2008-03-12 2009-03-10 암 치료 및 진단을 위한 표적 유전자인 ｃ2ｏｒｆ18

Country Status (9)

Country Link
US (1) US20110098339A1 (https=)
EP (1) EP2262541A4 (https=)
JP (1) JP2011518541A (https=)
KR (1) KR20100128326A (https=)
CN (1) CN102026672A (https=)
BR (1) BRPI0909310A2 (https=)
CA (1) CA2718382A1 (https=)
RU (1) RU2010141742A (https=)
WO (1) WO2009113295A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101406314B1 (ko) * 2011-07-19 2014-06-12 연세대학교 산학협력단 췌장암 암 줄기세포 특성에 기초한 췌장암의 치료용 타겟

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116794325B (zh) * 2023-06-15 2024-05-10 中山大学 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110593A2 (en) * 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
KR20070101610A (ko) * 2006-04-11 2007-10-17 주식회사 바이오인프라 Ａｎｔ２ 유전자의 발현을 억제하는 작은 간섭 ｒｎａ를이용한 암 유전자 치료 및 항암제 내성 극복방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101406314B1 (ko) * 2011-07-19 2014-06-12 연세대학교 산학협력단 췌장암 암 줄기세포 특성에 기초한 췌장암의 치료용 타겟

Also Published As

Publication number Publication date
CN102026672A (zh) 2011-04-20
EP2262541A1 (en) 2010-12-22
RU2010141742A (ru) 2012-04-20
CA2718382A1 (en) 2009-09-17
EP2262541A4 (en) 2012-02-29
JP2011518541A (ja) 2011-06-30
US20110098339A1 (en) 2011-04-28
WO2009113295A1 (en) 2009-09-17
BRPI0909310A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
JP5764822B2 (ja) がんの治療および診断の標的遺伝子としてのｐｒｍｔ１
CN101835894A (zh) Ebi3、dlx5、nptx1和cdkn3用作肺癌治疗和诊断的靶基因
JP2012511305A (ja) 癌の治療および診断の標的遺伝子としてのネクチン−４
JP2012509058A (ja) 前立腺癌を診断または治療するための方法
CN101855346A (zh) Pkib和naaladl2用作前列腺癌治疗和诊断的靶基因
JP2012501163A (ja) がんの治療および診断用の標的遺伝子としてのｃ１２ｏｒｆ４８
JP2012501167A (ja) 膵臓癌関連遺伝子ｔｔｌｌ４
EP1915622A2 (en) Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
KR20100128326A (ko) 암 치료 및 진단을 위한 표적 유전자인 ｃ2ｏｒｆ18
US20110070245A1 (en) Imp-1 oncogene as a therapeutic target and prognostic indicator for lung cancer
KR20110063490A (ko) 암 치료 및 진단의 표적 유전자인 ｓｙｎｇｒ４
KR20110067107A (ko) 종양 마커 및 암에 대한 치료적 표적으로서 ｔｂｃ１ｄ７
WO2012023290A1 (en) Rasef as tumor marker and therapeutic target for cancer
JP2012501162A (ja) 癌の治療および診断のための標的遺伝子としてのｏｉｐ５
JP2012501166A (ja) 乳癌関連遺伝子ｒｑｃｄ１
JP2013502901A (ja) がんの治療および診断の標的遺伝子としてのｅｒｃｃ６ｌ
JP2012501169A (ja) がん関連遺伝子ｌｇｎ／ｇｐｓｍ２
WO2011018898A1 (en) Cdc45l as tumor marker and therapeutic target for cancer
WO2012023288A1 (en) Fam161a as a target gene for cancer therapy and diagnosis
CN102575300A (zh) 肺癌治疗和诊断的靶基因cstf2

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000